Circulating soluble cytokine receptors and colorectal cancer risk

Gloria Y.F. Ho, Tao Wang, Siqun L. Zheng, Lesley Tinker, Jianfeng Xu, Thomas E. Rohan, Sylvia Wassertheil-Smoller, Xiaonan Xue, Leonard H. Augenlicht, Ulrike Peters, Amanda I. Phipps, Howard D. Strickler, Marc J. Gunter, Mary Cushman

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Background: Soluble cytokine receptors and receptor antagonist of proinflammatory cytokines can modify cytokine signaling and may affect cancer risk. Methods: In a case-cohort study nested within the Women's Health Initiative cohort of postmenopausal women, we assessed the associations of plasma levels of interleukin (IL)-1 receptor antagonist (IL-1Ra) and the soluble receptors of IL-1 (sIL-1R2), IL-6 (sIL-6R and sgp130), and TNF (sTNFR1 and sTNFR2) with risk of colorectal cancer in 433 cases and 821 subcohort subjects. Baseline levels of estradiol, insulin, leptin, IL-6, and TNF-α measured previously were also available for data analysis. Results: After adjusting for significant covariates, including age, race, smoking, colonoscopy history, waist circumference, and levels of estrogen, insulin, and leptin, relatively high levels of sIL-6R and sIL-1R2 were associated with reduced colorectal cancer risk [HRs comparing extreme quartiles (HRQ4-Q1) for sIL-6R, 0.56; 95% confidence interval (CI), 0.38-0.83; HRQ4-Q1 for sIL-1R2, 0.44; 95% CI, 0.29-0.67]. The associations with IL-1Ra, sgp130, sTNFR1, and sTNFR2 were null. The inverse association of sIL-1R2 with colorectal cancer risk persisted in cases diagnosed ≤5 and >5 years from baseline blood draw; the association with sIL-6R, however, was not evident in the latter group, possibly indicating that relatively low levels of sIL-6R in cases might be due to undiagnosed cancer at the time of blood draw. Conclusions: High circulating levels of sIL-1R2 may be protective against colorectal carcinogenesis and/or be a marker of reduced risk for the disease. Impact: sIL-1R2 has potential to be a chemopreventive and/or immunotherapeutic agent in inflammationrelated diseases. Cancer Epidemiol Biomarkers Prev; 23(1); 179-88.

Original languageEnglish (US)
Pages (from-to)179-188
Number of pages10
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint Dive into the research topics of 'Circulating soluble cytokine receptors and colorectal cancer risk'. Together they form a unique fingerprint.

  • Cite this

    Ho, G. Y. F., Wang, T., Zheng, S. L., Tinker, L., Xu, J., Rohan, T. E., Wassertheil-Smoller, S., Xue, X., Augenlicht, L. H., Peters, U., Phipps, A. I., Strickler, H. D., Gunter, M. J., & Cushman, M. (2014). Circulating soluble cytokine receptors and colorectal cancer risk. Cancer Epidemiology Biomarkers and Prevention, 23(1), 179-188. https://doi.org/10.1158/1055-9965.EPI-13-0545